Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO, May 12, 2022 SAN DIEGO, May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc...
Kuznicki Law PLLC is investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the proposed transaction...
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader PR Newswire SAN DIEGO and EWING, N.J., April 13, 2022 Transaction Expected to be Immediately Accretive to...
EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug...
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2...
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and...
EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.